COVID-19 Latest Updates

Hematology: Clinical Research Program

Banner

Hematology: Clinical Studies Open For Enrollment

 

Allogeneic Stem Cell Transplant to Induce Mixed Donor Chimerism in Patients with Sickle Cell Disease & Thalassemia NYMC 556

Eligibility

  • Subject is 30 years of age or younger
  • Diagnosis of Homozygous Hemoglobin S Disease or Heterozygous Hemoglobin Sickle Cell (SC) or S 0/+ thalassemia, or Sickle/variant resulting in Chronic Hemolytic Anemia with hemoglobin (HgB) less than or equal to 10 mg/dL

Enrollment Status: Enrolling

Study Information

ClinicalTrials.gov | NCT00408447

Principal Investigator

Mitchell S. Cairo, MD

Contact for Study Screening

Lauren_Harrison@nymc.edu

 

Analysis of Patients Treated for Chronic Granulomatous Disease

Enrollment Status: Enrolling

Principal Investigator

Jordan Brittni Milner, MD

Contact for Study Screening

Lauren_Harrison@nymc.edu

 

A prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children with SCID Disorders

Enrollment Status: Enrolling

Principal Investigator

Jordan Brittni Milner, MD

Contact for Study Screening

Lauren_Harrison@nymc.edu

 

The use of dose dense rituximab for high risk patients with newly diagnosed acute immune thrombocytopenic purpura

Enrollment Status: Enrolling

Principal Investigator

Jordan Brittni Milner, MD

Contact for Study Screening

Lauren_Harrison@nymc.edu

 

A Pilot Study to Determine the Safety of Defibrotide in Children with High Risk Kawasaki Disease (NYMC-204)

Eligibility

  • Subject is 11 years of age or younger
  • Kawasaki disease presumptive diagnosis and initiation of defibrotide within 96 hours from the conclusion of IVIG treatment 

Enrollment Status: Enrolling

Study Information

ClinicalTrials.gov | NCT04777422

Principal Investigator

Mitchell S. Cairo, MD

Contact for Study Screening

Lauren_Harrison@nymc.edu